Brooks Laboratories (BROOKS.NS) Stock Price

Brooks Laboratories Price

CLOSED
74.88
​
Market closed

Revenue has compounded at 7.1% per year over the past 19 years to 857.38 M INR. Earnings per share have grown at 17.6% per year over the last 19 years. Brooks Laboratories's net margin stands at 28.7%, up from -21.2% several years earlier.

Brooks Laboratories stock price

Access this data via the Eulerpool API

Brooks Laboratories business model & stock analysis

Brooks Laboratories Ltd. is a research and development driven pharmaceutical manufacturing company. The company is headquartered in Mumbai, Maharashtra and currently employs 296 full-time employees. The company went IPO on 2011-09-02. The firm operates through the Pharmaceuticals segment. The company manufactures various pharmaceutical dosage forms, including injections, tablets, dry syrup and eye/ear drops. Its products under Carbapenem category includes Imipenem 250mg + Cilastatin 250mg, Imipenem 500mg + Cilastatin 500mg, Meropenem 125mg, Meropenem 250mg, Meropenem 500mg, Meropenem 1000mg, Meropenem 1000mg+Sulbactam 500mg, Meropenem 1000mg+Tazobactam 500mg, Doripenem 500mg and Doripenem 1000mg. The company offers Penicillins in the form of injections, tablets and dry syrup. Its General category of products include liquid injections, dry powder injections and eye/ear drops. Its liquid injections include Iron sucrose 100mg/5ml, among others. The firm has manufacturing plants at Baddi, Himachal Pradesh. The firm manufactures and markets the pharmaceuticals nationally and internationally to various regulated markets.

Frequently asked questions about Brooks Laboratories

Converted at the current exchange rate, the Brooks Laboratories share trades at 0.69 EUR (74.88 INR).

The revenue of Brooks Laboratories is 857.38 M INR. This figure is based on current financial data and reflects the company's business performance.

The profit of Brooks Laboratories is 245.84 M INR. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Brooks Laboratories is currently 8.97. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Brooks Laboratories stock.

The price-to-sales ratio (P/S) of Brooks Laboratories is currently 2.57. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Brooks Laboratories stock.

The Eulerpool Quality Score for Brooks Laboratories is 3/10.

The ISIN of Brooks Laboratories is INE650L01011. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Brooks Laboratories is BROOKS.NS. The ticker symbol is used to trade Brooks Laboratories shares on the stock exchange.

Fair ValueTerminal
62.90 INR
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Life Sciences Tools & Services
Number of shares
Employees
Revenue per Employee
2.90 M INR
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Currency
INR
Initial public offering
Sep 2, 2011
ISIN
INE650L01011
Cusip
Y0975G108
Market capitalization
2.21 B INRMid Cap
52-Week Range
PEG
—
P/E ratio
P/Ee
—
P/S
P/Se
—
EV/EBIT
40.51
P/B Ratio
1.80
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
18.74 %
Last updated Oct 10, 2026, 6:23 PM

Brooks Laboratories Peer Group

Brooks Laboratories FIGI

BKL:IN · BBG0019PGXC9BKL:IB · BBG0019PGXD8BKL:IS · BBG0019PGXG5BKL:IG · BBG003NWB4V2